Back
47
98
Day Range
$6.52
$6.88
52-Week Range
$3.73
$10.32
Volume
1,828,145
50D / 200D Avg
$7.85
/
$7.50
Prev Close
$6.52
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 6.2 | 0.4 |
| P/B | 7.2 | 2.9 |
| ROE % | 621.9 | 3.8 |
| Net Margin % | 9.3 | 3.9 |
| Rev Growth 5Y % | 9.7 | 10.0 |
| D/E | 6.9 | 0.2 |
Key Takeaways
Revenue grew 9.73% annually over 5 years — modest growth
ROE of 621.89% indicates high profitability
Debt/Equity of 6.91 — high leverage
Generating 114.79M in free cash flow
P/E of 6.23 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10.46%
Growth
Revenue Growth (5Y)
9.73%
Revenue (1Y)20.19%
Earnings (1Y)N/A
FCF Growth (3Y)163.32%
Quality
Return on Equity
621.89%
ROIC12.94%
Net Margin9.25%
Op. Margin10.91%
Safety
Debt / Equity
6.91
Current Ratio1.32
Interest Coverage1.89
Valuation
P/E Ratio
6.23
P/B Ratio7.21
EV/EBITDA9.62
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 20.19% | Revenue Growth (3Y) | 13.31% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 9.73% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 2.43B | Net Income (TTM) | 225.03M |
| ROE | 621.89% | ROA | 11.18% |
| Gross Margin | 33.09% | Operating Margin | 10.91% |
| Net Margin | 9.25% | Free Cash Flow (TTM) | 114.79M |
| ROIC | 12.94% | FCF Growth (3Y) | 163.32% |
| Safety | |||
| Debt / Equity | 6.91 | Current Ratio | 1.32 |
| Interest Coverage | 1.89 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 6.23 | P/B Ratio | 7.21 |
| P/S Ratio | 0.58 | PEG Ratio | 0.00 |
| EV/EBITDA | 9.62 | Dividend Yield | 0.00% |
| Market Cap | 1.40B | Enterprise Value | 2.55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.43B | 2.02B | 1.90B | 1.79B | 1.68B |
| Net Income | 225.03M | -10.93M | -134.52M | -662.03M | -117.04M |
| EPS (Diluted) | 1.05 | -0.06 | -0.71 | -3.57 | -0.63 |
| Gross Profit | 805.15M | 635.54M | 595.43M | 553.23M | 542.40M |
| Operating Income | 265.38M | 139.79M | 8.07M | -642.28M | -36.11M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.01B | 1.66B | 1.61B | 1.71B | 2.33B |
| Total Liabilities | 1.82B | 1.79B | 1.74B | 1.72B | 1.70B |
| Shareholders' Equity | 194.46M | -122.09M | -127.44M | -4.18M | 637.95M |
| Total Debt | 1.34B | 1.50B | 1.50B | 1.36B | 1.30B |
| Cash & Equivalents | 193.26M | 84.29M | 43.94M | 19.22M | 30.49M |
| Current Assets | 560.23M | 392.67M | 314.89M | 269.75M | 279.22M |
| Current Liabilities | 424.46M | 402.17M | 354.76M | 326.50M | 344.83M |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#204 of 613
#3 of 655
Recent Activity
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026